Catabasis Pharmaceuticals
Latest round
- Series B
Last raised
- Mar 2015
Total raised
- $72M
Investors
- 6
About Catabasis Pharmaceuticals
Based in Massachusetts, US and founded in 2008, Catabasis Pharmaceuticals, Inc. develops a monoclonal antibody inhibitor of plasma kallikrein as a drug for patients with Hereditary Angioedema, a rare genetic disorder. In 2012, Catabasis Pharmaceuticals, Inc. The company works with pharmaceutical companies, by offering the drug application for patients with hereditary angioedema and dyslipidemias. Catabasis Pharmaceuticals, Inc. develops QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that helps patients build protective protein produced by the immune system from rare genetic disorders. The pharmaceutical institutions will approach the company by checking the process and effects of the drug during the clinical trial. If accepted, pharmaceuticals will then purchase the drug and manufacture it for public consumption through drug stores. The company generates revenue by offering their drug application intended for patients with rare genetic disorders such as hereditary angioedema and dyslipidemias to pharmaceutical institutions. The company plans to file the new drug application for QLS-215 in 2022 and initiate a phase 1 clinical trial in late 2022.
Who invested in Catabasis Pharmaceuticals
6 investors across 5 rounds
See all investors in Catabasis Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Catabasis Pharmaceuticals
Who invested in Catabasis Pharmaceuticals?
Catabasis Pharmaceuticals has 6 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Catabasis Pharmaceuticals raised?
Catabasis Pharmaceuticals has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Catabasis Pharmaceuticals last raise money?
Catabasis Pharmaceuticals's most recent round on record is a Series B, in Mar 2015.
What does Catabasis Pharmaceuticals do?
Based in Massachusetts, US and founded in 2008, Catabasis Pharmaceuticals, Inc.
Where is Catabasis Pharmaceuticals headquartered?
Catabasis Pharmaceuticals is headquartered in Boston, US.
Which VCs invest in companies like Catabasis Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Catabasis Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Catabasis Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.